BioCentury | Jul 6, 2009
Finance

2Q Approvals & Setbacks

...withchronic kidney disease (CKD) Angiotech Pharmaceuticals Inc. (TSX:ANP; NASDAQ:ANPI)/ Boston Scientific Corp. (NYSE:BSX) FDA approves Taxus Liberte Atom paclitaxel-eluting coronary stent system...
BioCentury | Jun 1, 2009
Finance

Ebb & Flow

...in Toronto and $0.54 (46%) to $1.72 on NASDAQ on Wednesday after FDA approved the Taxus Liberte Atom paclitaxel-eluting coronary stent system...
BioCentury | Jun 1, 2009
Clinical News

Taxus Liberte Atom Paclitaxel-Eluting Coronary Stent System regulatory update

...FDA approved the Taxus Liberte Atom Paclitaxel-Eluting Coronary Stent System to treat small-vessel coronary artery disease (CAD) in vessels as small as...
...1997). Angiotech Pharmaceuticals Inc. (TSX:ANP; NASDAQ:ANPI), Vancouver, B.C. Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Product: Taxus Liberte Atom Paclitaxel-Eluting Coronary Stent System...
BioCentury | May 28, 2009
Company News

Angiotech up after Taxus approval

...Pharmaceuticals Inc. (TSX:ANP; NASDAQ:ANPI) gained C$0.57 (43%) to C$1.89 on Wednesday after FDA approved the Taxus Liberte Atom paclitaxel-eluting coronary stent system...
Items per page:
1 - 4 of 4